产品
编 号：F015618
分子式：C16H14F3N3O2S
分子量：369.36
分子式：C16H14F3N3O2S
分子量：369.36
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
400
In-stock
1g
528
In-stock
5g
1971
In-stock
结构图
CAS No: 103577-45-3
产品详情
生物活性：
Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
体内研究：
Lansoprazole（20-40 mg/kg）治疗显着减轻 STZ 和 HFD 引起的记忆缺陷、生化和组织病理学改变。Lansoprazole（20 mg/kg 和 40 mg/kg，口服）显着降低 STZ 和 HFD 诱导的 AChE 活性增加。Lansoprazole（20 mg/kg 和 40 mg/kg，口服）显着降低 STZ 和 HFD 引起的脑 MPO 水平升高。与对照动物相比，用 Lansoprazole（20 mg/kg 和 40 mg/kg，口服）处理的其他 HFD 小鼠体重显着下降。Animal Model:Swiss albino mice (20–25 g) of either sex.
Dosage:20 mg/kg, 40 mg/kg.
Administration:PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result:Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.
体外研究：
0.3 至 3 μM 的 Lansoprazole 以浓度依赖性方式抑制胃酸形成 (IC50 为 0.76 μM)。 Lansoprazole (30-300 μM) 均诱导浓度依赖性、可逆和可重复的动脉舒张。
Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
体内研究：
Lansoprazole（20-40 mg/kg）治疗显着减轻 STZ 和 HFD 引起的记忆缺陷、生化和组织病理学改变。Lansoprazole（20 mg/kg 和 40 mg/kg，口服）显着降低 STZ 和 HFD 诱导的 AChE 活性增加。Lansoprazole（20 mg/kg 和 40 mg/kg，口服）显着降低 STZ 和 HFD 引起的脑 MPO 水平升高。与对照动物相比，用 Lansoprazole（20 mg/kg 和 40 mg/kg，口服）处理的其他 HFD 小鼠体重显着下降。Animal Model:Swiss albino mice (20–25 g) of either sex.
Dosage:20 mg/kg, 40 mg/kg.
Administration:PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result:Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.
体外研究：
0.3 至 3 μM 的 Lansoprazole 以浓度依赖性方式抑制胃酸形成 (IC50 为 0.76 μM)。 Lansoprazole (30-300 μM) 均诱导浓度依赖性、可逆和可重复的动脉舒张。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备